Company Overview of Nestlé Health Science S.A.
Nestlé Health Science S.A. engages in the manufacture and distribution of nutritional solutions for consumers, patients, and its partners in healthcare market worldwide. It offers diagnostics, devices, and drugs for inborn errors of metabolism, paediatric and acute care, obesity care, healthy ageing, and gastrointestinal and brain health; clinical nutritional solutions for metabolic disorders; diagnostics and pharmaceuticals in gastroenterology and oncology; prescription medical foods for the brain and metabolic disorders; botanical-based nutrients for gastrointestinal disorders; an assessment tool to help healthcare professionals identify cases of cow's milk protein allergy or CMPA in infan...
Avenue Reller 14
Founded in 2010
Key Executives for Nestlé Health Science S.A.
Chief Executive Officer and Director
Director and Chief Executive Officer of Nestlé S A
Chief Executive Officer of Accera and President of Accera
Head of Nestlé Institute of Health Sciences and Director
Compensation as of Fiscal Year 2016.
Nestlé Health Science S.A. Key Developments
DBV Technologies and Nestle Health Science Form Collaboration to Develop and Commercialize Novel Diagnostic Test for Pediatric Milk Allergy
May 31 16
DBV Technologies and Nestle Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy. Collaboration will support DBV's Mission to Develop Transformational Product Candidates for the Care of Pediatric Patients Suffering from Food Allergies. Under the Terms of the Agreement, DBV will Develop a Ready-To-Use Test to Diagnose Allergy to Cow's Milk Protein. DBV is Eligible to Receive up to €100 Million in Potential Development, Registration and Commercial Milestones, while Granting Global Commercialization Rights to Nestle Heath Science. DBV Technologies announced that it has entered into an exclusive global collaboration with Nestle Health Science for the development and, if approved, commercialization of MAG1C, an innovative, ready-to-use and standardized atopy patch-test for the diagnosis of Cow's Milk allergy (CMPA) in infants and toddlers. By leveraging its proprietary Viaskin technology platform, DBV will be responsible for developing this new pharmaceutical product candidate, and if approved by the appropriate regulatory agencies, Nestle Health Science will support its worldwide commercialization through its range of nutritional solutions tailor-made for babies and young children suffering from CMPA and other food allergies and intolerances. Under the terms of the agreement, DBV will be eligible to receive up to €100 million in development, registration and commercial milestones, including an upfront payment of €10 million. DBV will be responsible for performing development activities up through a pivotal Phase III clinical program, following which Nestlé Health Science has the exclusive right to commercialize the product globally, if approved. DBV will pay for all development-related costs of MAG1C, including a worldwide clinical program, as well as manufacturing costs. If MAG1C is successfully manufactured by DBV, the company will receive a supply price with a mark-up from Nestlé Health Science. In addition, Nestlé Health Science will pay to DBV tiered royalties on global product sales. This new diagnostic test is expected to be submitted for approval to regulatory authorities worldwide by 2021.
Seres Therapeutics Announces Strategic Collaboration with Nestle Health Science
Jan 14 16
Seres Therapeutics has entered into an agreement with Nestle Health Science for the development and commercialization outside of the United States and Canada for its product candidates in development for Clostridium difficile infection (CDI) and inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The agreement will support the expansion of Seres' portfolio in markets outside of the United States and Canada and provide substantial financial support for Seres' ongoing research and development. Seres retains full commercial rights to its entire portfolio of product candidates in the United States and Canada, where the company plans to build its own commercial organization. Under the agreement, Seres granted Nestle Health Science commercial rights in global markets outside of the United States and Canada to SER-109 and SER-262 for CDI, and SER-287 and SER-301 for IBD. The U.S. Food and Drug Administration (FDA) has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. In exchange for commercial rights, Nestle Health Science agreed to provide Seres with an upfront payment of $120 million in cash and a series of contingent payments for development and sales milestones and tiered royalties on sales ranging from the high single digits percentages up to the high teens for all products. Nestle Health Science agreed to contribute to certain development efforts, including 33% of expenses for potential global Phase 3 studies for SER-287, SER-301 and SER-262. The full potential value of the up-front payment, milestones and royalties payable by Nestle Health Science is over $1.9 billion, assuming all products receive regulatory approval and are successfully commercialized. Seres expects to receive a total of $30 million in milestone payments in 2016 associated with the planned initiation of a Phase 1b study for SER-262 in primary CDI and the anticipated start of the Phase 3 trial for SER-109 in recurrent CDI. The upfront payment to be received under the agreement is expected to help fund the late-stage development of Seres' lead programs, and drive the continued growth of Seres' pipeline in a variety of conditions where addressing the microbiome could be an effective clinical strategy.
Lipid Therapeutics GmbH Signs Licensing Agreement with Nestlé Health Science S.A
Sep 18 15
Lipid Therapeutics GmbH has entered into a licensing agreement with Nestle Health Science S.A. for exclusive rights to Lipid Therapeutics' LT-02 compound (phosphatidylcholine), a novel barrier function therapy for patients with mild-to-moderate ulcerative colitis (UC), worldwide excluding Europe and Australia. The terms of the license include an upfront fee, milestones payments and royalties on net sales. Under the agreement Nestle Health is responsible for the continued development and commercialization of LT-02 in its territories, with Phase III clinical trials in the US planned to start in 2016. The trials will primarily assess LT-02 as an add-on therapy in patients with UC not adequately responding to standard doses of 5-aminosalicylic acid, the current standard treatment for the condition.
Similar Private Companies By Industry
Recent Private Companies Transactions